# BPC-157 TB-500: The Wolverine Blend, Tagged to the Literature > BPC-157 TB-500 is the Wolverine blend — BPC-157 paired with the TB-500 actin-binding fragment. Two mechanisms, two cited literatures, and no controlled combination trial. A research digest. Two peptides, two mechanisms, two separate bodies of evidence — and not one controlled trial of the combination. Every number on this wall is tagged to its constituent and cited to its source. ## Two peptides sprayed under one name BPC-157 TB-500 is the research-community name for a two-peptide pairing, tagged on gym forums and supplier sites as the "Wolverine" blend. It is not a single chemical entity, not an approved drug, and not a thing any controlled trial has ever tested as a unit. It is two distinct synthetic peptides put in one vial. The first is BPC-157 — Body Protection Compound 157, a 15-amino-acid pentadecapeptide (`Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val`, MW ~1419.5 Da) derived from a protein found in human gastric juice. In preclinical models it works locally: it up-regulates VEGFR2 and drives downstream Akt-eNOS angiogenic and cytoprotective signaling [2]. The second is TB-500 — a synthetic N-acetylated heptapeptide (`Ac-LKKTETQ`, MW ~889.0 Da) corresponding to the actin-binding region (residues 17-23) of Thymosin Beta-4 [5]. It works on the cytoskeleton, sequestering monomeric actin to regulate the cell migration that underlies repair [3]. The "synergy" claim rests on those two mechanisms being complementary and largely non-overlapping. That is a reasonable extrapolation. It is also exactly that — an extrapolation. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together [6]. This site reads the evidence one constituent at a time, marks every blend-level gap, and keeps the FDA 503A access status in plain sight. For the regulatory picture, start with [the Wolverine legal status and FDA 503A category](/legal-status). ## What the Wolverine peptide blend is ### What is the Wolverine peptide blend? It is a research-community name for a two-peptide pairing of BPC-157 (a cytoprotective, angiogenic pentadecapeptide) with TB-500 (the synthetic `Ac-LKKTETQ` actin-binding fragment of Thymosin Beta-4), discussed as a tissue-repair "stack." It is not a single chemical entity and not an approved product. Commercial vials commonly pair the two at a combined mass — for example `10 mg + 10 mg` — but no standardized composition or ratio is clinically validated. ### What is BPC-157 and TB-500? BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a human gastric-juice protein. TB-500 is a synthetic N-acetylated heptapeptide (`Ac-LKKTETQ`) corresponding to the actin-binding region of Thymosin Beta-4 [5]. The blend pairs the two for their complementary proposed tissue-repair mechanisms — a local angiogenic signal and a cytoskeletal migration signal. ### What is the difference between BPC-157 and TB-500? BPC-157 is a 15-amino-acid gastric-juice-derived peptide acting via VEGFR2/eNOS angiogenesis and growth-hormone-receptor sensitization [2]. TB-500 is a 7-amino-acid actin-binding fragment of Thymosin Beta-4 acting via G-actin sequestration and cell migration [3]. Different sequences, different sizes, different proposed mechanisms — paired, not merged. ### What is the 'Wolverine stack'? "Wolverine stack" is the research-community term for the BPC-157 + TB-500 pairing. It is a forum and supplier label, not an approved product or a single validated formulation. The name is also conflated with the X-Men character, which is why the cleaner search signal for the pairing is "BPC-157 TB-500." ## BPC-157 and TB-500: How the Two Peptides Are Paired BPC-157 and TB-500 are paired on a two-mechanism rationale. BPC-157 supplies the local signal: VEGFR2 up-regulation feeding an Akt-eNOS angiogenic and cytoprotective cascade, plus growth-hormone-receptor sensitization in tendon fibroblasts [2]. TB-500 supplies the cytoskeletal signal: its `LKKTETQ` helix binds monomeric G-actin 1:1, regulating the actin dynamics that drive cell migration and re-epithelialization [3]. Those are described as parallel routes to the same end — better-perfused, faster-migrating, more rapidly resurfaced tissue. On paper they slot together cleanly, which is the whole appeal of the pairing. The honest caveat sits directly under the rationale: no controlled combination study has defined a synergy ratio, dose, or endpoint for the two peptides given together. The 2025 HSS Journal systematic review of BPC-157 — 36 studies, only one in humans — makes no mention of TB-500 or combination use at all [6]. Every "synergy" statement about the Wolverine blend is therefore an extrapolation from two separately characterized mechanisms, not a finding from a study of the blend. There is a second gap stacked on the first. Most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4 (~4963 Da), not the `Ac-LKKTETQ` 7-mer that is actually sold [4]. The blend leans on full-length-protein data for one of its two components — a caveat the pairing inherits and rarely states. See [the research literature on BPC-157 and TB-500](/research) for the mechanism evidence in full. ## How this wall is organized This is an editorial research digest, not a clinic and not a storefront. It indexes what the published literature on each constituent of the Wolverine blend establishes — and, just as deliberately, what it does not. The evidence pages read one peptide at a time. [The research literature on BPC-157 and TB-500](/research) covers the mechanisms and the foundational studies. [BPC-157 TB-500 benefits in recovery research](/recovery-research) collects the tendon, ligament, muscle, and wound-repair findings — all preclinical, all single-compound. [BPC-157 TB-500 dosage in the research literature](/dosage) frames the species-and-route context without offering a human protocol, because none is validated. The access pages keep the regulatory record first. [The Wolverine legal status and FDA 503A category](/legal-status) states the present-tense FDA position, with citations. The [common questions about the Wolverine blend](/faq) answer the 25 most-asked questions directly, and [the cited studies and references](/references) list every source with its DOI or PubMed link. Nothing here is medical or legal advice. --- A street-wall research digest on the BPC-157 TB-500 Wolverine blend — each peptide tagged to its own studies, every blend-level gap sprayed in plain sight beside the FDA 503A line, with no clinic behind the wall and nothing here to dispense.